Interleukin-27 Signaling Promotes Immunity against Endogenously Arising Murine Tumors
Author(s) -
Karlo Dante T. Natividad,
Simon Junankar,
Norhanani Mohd Redzwan,
Radhika Nair,
Rushika C. Wirasinha,
Charles M. King,
Robert Brink,
Alexander Swarbrick,
Marcel Batten
Publication year - 2013
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0057469
Subject(s) - immunosurveillance , biology , immune system , cancer research , immunology , cytokine , cd8 , immunity , immunotherapy , context (archaeology) , fibrosarcoma , genetics , paleontology
Interleukin-27 (IL-27) is a pleiotropic cytokine but its immunosuppressive effects predominate during many in vivo immunological challenges. Despite this, evidence from tumor cell line transfer models suggested that IL-27 could promote immune responses in the tumor context. However, the role of IL-27 in immunity against tumors that develop in situ and in tumor immunosurveillance remain undefined. In this study, we demonstrate that tumor development and growth are accelerated in IL-27 receptor α (Il27ra) -deficient mice. Enhanced tumor growth in both carcinogen-induced fibrosarcoma and oncogene-driven mammary carcinoma was associated with decreased interferon-γ production by CD4 and CD8 T cells and increased numbers of regulatory T-cells (T reg ). This is the first study to show that IL-27 promotes protective immune responses against endogenous tumors, which is critical as the basis for future development of an IL-27 based therapeutic agent.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom